# A ‘Standard of Care PLUS’ Model for Preterm Birth Prevention: Integrating Nutrient and Gene Variant Analysis with Targeted Interventions

**Authors:** Leslie P. Stone, Emily Stone Rydbom, P. Michael Stone, Daniel Kim

PMC · DOI: 10.3390/jpm16030134 · 2026-02-28

## TL;DR

This study explores a new model combining nutrient and gene analysis with targeted interventions to reduce preterm birth and other adverse pregnancy outcomes.

## Contribution

A novel 'Standard of Care PLUS' model integrating personalized nutrition and gene variant analysis with targeted interventions is proposed and evaluated.

## Key findings

- The PLUS model was associated with significant reductions in preterm birth and other adverse outcomes in the Oregon cohort.
- Pooled analyses showed significant reductions in all five adverse outcomes compared to standard care.
- No significant differences were found between virtual and in-person delivery of the PLUS model.

## Abstract

Background/Objectives: The rates of adverse maternal and neonatal outcomes—including preterm birth < 37 weeks’ gestation (PTB), hypertensive disorders of pregnancy (HDP), gestational diabetes mellitus (GDM), small for gestational age (SGA), and large for gestational age (LGA)—remain elevated in the United States. Preventive strategies beyond the current standard of care (SOC) may be needed, particularly in diverse and socioeconomically vulnerable populations. The study evaluated a targeted diet and lifestyle intervention incorporating selected nutrient and gene variant analysis with personalized trimester-based counseling and supplementation (Standard of Care Plus, PLUS). Methods: The prospective observational study compared outcomes among participants receiving PLUS in addition to SOC with regional SOC data. A Nevada PLUS cohort (n = 15), consisting of high-risk participants with 100% Medicaid coverage, received the intervention virtually. An Oregon PLUS cohort (n = 387), consisting of moderate-risk participants with approximately 50% Medicaid coverage, received PLUS through in-person group sessions. Outcomes were compared with regional SOC rates and between PLUS cohorts. Cochran–Mantel–Haenszel (CMH) analyses were performed to account for site-level differences in pooled analyses. Primary outcome was PTB < 37 weeks’ gestation; secondary outcomes included HDP, GDM, SGA, and LGA. Results: The Nevada PLUS application was associated with lower adverse outcome rates compared with regional SOC; however, statistical significance was not observed, likely reflecting limited sample size. The Oregon PLUS cohort experienced statistically significant association with reductions across all five outcomes (all p < 0.001) compared to regional SOC. No statistically significant differences were observed between the Nevada (virtual) and Oregon (in-person) PLUS cohorts. In pooled analyses (n = 402), significant reductions compared with SOC were observed for PTB (RR = 0.23), HDP (RR = 0.11), GDM (RR = 0.06), SGA (RR = 0.25), and LGA (RR = 0.35) (all p < 0.001). Conclusions: The implementation of selected nutrient and gene variant analysis combined with targeted nutritional and lifestyle interventions, delivered in collaboration with standard obstetric care, was associated with reduced adverse maternal and neonatal outcomes. Interpretation of virtual delivery remains limited by small sample size.

## Linked entities

- **Diseases:** gestational diabetes mellitus (MONDO:0005406)

## Full-text entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, MTHFD1 (methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1) [NCBI Gene 4522] {aka CIMAH, MTHFC, MTHFD}, MAOA (monoamine oxidase A) [NCBI Gene 4128] {aka BRNRS, MAO-A}, AHR (aryl hydrocarbon receptor) [NCBI Gene 196] {aka FVH3, RP85, bHLHe76}, IGF2BP2 (insulin like growth factor 2 mRNA binding protein 2) [NCBI Gene 10644] {aka IMP-2, IMP2, VICKZ2}, CBS (cystathionine beta-synthase) [NCBI Gene 875] {aka HIP4}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, CHDH (choline dehydrogenase) [NCBI Gene 55349], CYP1A1 (cytochrome P450 family 1 subfamily A member 1) [NCBI Gene 1543] {aka AHH, CP11, CYP1, CYPIA1, P1-450, P450-C}, CYP1A2 (cytochrome P450 family 1 subfamily A member 2) [NCBI Gene 1544] {aka CP12, CYPIA2, P3-450, P450(PA)}, ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) [NCBI Gene 5167] {aka ARHR2, COLED, M6S1, NPP1, NPPS, PC-1}, GCK (glucokinase) [NCBI Gene 2645] {aka FGQTL3, GK, GLK, HHF3, HK4, HKIV}, GSTA1 (glutathione S-transferase alpha 1) [NCBI Gene 2938] {aka GST-epsilon, GST2, GSTA1-1, GTH1}, MTHFR (methylenetetrahydrofolate reductase) [NCBI Gene 4524], VDR (vitamin D receptor) [NCBI Gene 7421] {aka NR1I1, PPP1R163}, PEMT (phosphatidylethanolamine N-methyltransferase) [NCBI Gene 10400] {aka PEAMT, PEMPT, PEMT2, PLMT}, GSTM1 (glutathione S-transferase mu 1) [NCBI Gene 2944] {aka GST1, GSTM1-1, GSTM1a-1a, GSTM1b-1b, GTH4, GTM1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, COMT (catechol-O-methyltransferase) [NCBI Gene 1312] {aka HEL-S-98n}, GSTT1 (glutathione S-transferase theta 1) [NCBI Gene 2952], GSTP1 (glutathione S-transferase pi 1) [NCBI Gene 2950] {aka DFN7, FAEES3, GST3, GSTP, GSTP1-1, HEL-S-22}, MTNR1B (melatonin receptor 1B) [NCBI Gene 4544] {aka FGQTL2, MEL-1B-R, MT2}
- **Diseases:** injury to (MESH:D014947), eczema (MESH:D004485), NCD (MESH:D000073296), HIV (MESH:D015658), gain (MESH:D015430), DHA deficiency (MESH:D015223), anemia (MESH:D000740), miscarriage (MESH:D000022), insulin resistance (MESH:D007333), allergic, neurodevelopmental, and metabolic disorders (MESH:D024821), hemoglobin deficiency (MESH:D006445), Hepatitis B (MESH:D006509), iron deficiency anemia (MESH:D018798), vitamin D deficiency (MESH:D014808), PreE (MESH:D011225), micronutrient insufficiencies (MESH:D000309), osteoporosis (MESH:D010024), SOC (MESH:D003428), CVD (MESH:D002318), PLUS (OMIM:617303), infectious disease (MESH:D003141), atopy (MESH:C564133), fetal growth restriction (MESH:D005317), metabolic dysregulation (MESH:D021081), Rubella (MESH:D012409), gut dysbiosis (MESH:D064806), asthma (MESH:D001249), Chronic HTN (MESH:D006973), DM (MESH:D009223), HDP (MESH:D046110), allergy (MESH:D004342), deaths (MESH:D003643), nutritional deficiencies (MESH:D044342), inflammation (MESH:D007249), neurodevelopmental delay (MESH:D006968), obesity (MESH:D009765), GDM (MESH:D016640), cancers (MESH:D009369), maternal and (MESH:D000079262), Free carnitine deficiency (MESH:C536778), diabetes (MESH:D003920), PTB (MESH:D047928), neural tube defects (MESH:D009436), autism (MESH:D001321), chronic disease (MESH:D002908), micronutrient deficiencies (MESH:D007153), iron (MESH:D000090463), Zinc deficiency (MESH:C564286), impaired glucose metabolism (MESH:D044882), morbidities (OMIM:614963)
- **Chemicals:** polyphenols (MESH:D059808), 25(OH)D (-), DHA (MESH:D004281), Vitamin D (MESH:D014807), folate (MESH:D005492), riboflavin (MESH:D012256), betaine (MESH:D001622), carbohydrate (MESH:D002241), 5-methyltetrahydrofolate (MESH:C005984), Iron (MESH:D007501), calcium (MESH:D002118), vitamin D3 (MESH:D002762), niacin (MESH:D009525), magnesium (MESH:D008274), alcohol (MESH:D000438), vitamin B12 (MESH:D014805), choline (MESH:D002794), iodine (MESH:D007455), B12 (MESH:C034730), 25-hydroxy cholecalciferol (MESH:D002112), Glucose (MESH:D005947), carnitine (MESH:D002331), Lutein (MESH:D014975), acetate (MESH:D000085), formate (MESH:C030544), D (MESH:D003903), omega-3 fatty acids (MESH:D015525), fatty acids (MESH:D005227), zinc (MESH:D015032)
- **Species:** Bifidobacterium (genus) [taxon 1678], Lactobacillus (genus) [taxon 1578], Homo sapiens (human, species) [taxon 9606], Lactococcus lactis (species) [taxon 1358], gut metagenome (species) [taxon 749906]
- **Mutations:** A>G, A/C, C/T, rs10830963, -30G>A, 677C>T, 1298A>C, 66 A>G, G/A, Ile105Val, Leu78Arg, -930A/G, Val66Met, Arg554Lys

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027778/full.md

---
Source: https://tomesphere.com/paper/PMC13027778